Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward

Advanced Drug Delivery Reviews

Volumn 64, Issue 13, 2012, Pages 1385-1393

  Moghimi, S Moein ^a   Wibroe, Peter P ^a   Helvig, Shen Y ^a   Farhangrazi, Z Shadi ^b   Hunter, A Christy ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Nikkia Biosystems Inc   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acute allergic like reactions; Anaphylatoxins; C3a receptor; C5a receptor; Complement system; Gene expression; Single nucleotide polymorphism

Indexed keywords

ACUTE ALLERGIC-LIKE REACTIONS; ANAPHYLATOXINS; C3A RECEPTOR; C5A RECEPTOR; COMPLEMENT SYSTEMS; SINGLE NUCLEOTIDE POLYMORPHISMS;

ASSOCIATION REACTIONS; GENE EXPRESSION; HEALTH CARE;

MEDICAL NANOTECHNOLOGY;

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR H; CYTOKINE; DOXORUBICIN; FICOLIN; MANNOSE BINDING LECTIN; PACLITAXEL;

ADVERSE DRUG REACTION; AUTONOMIC DYSFUNCTION; CARDIOVASCULAR DISEASE; COMPLEMENT ACTIVATION; DNA POLYMORPHISM; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENOMICS; HEALTH CARE COST; HEREDITY; HUMAN; HYPERSENSITIVITY; INFUSION RELATED REACTION; INNATE IMMUNITY; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; MEDICAL DECISION MAKING; MUCOSAL DISEASE; NANOMEDICINE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOMATIC DISORDER; REVIEW; RISK ASSESSMENT; SKIN DISEASE;

ANIMALS; GENOMICS; HUMANS; INFUSIONS, INTRAVENOUS; NANOMEDICINE; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 84867669079     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.05.010     Document Type: Review

References (125)

1. Moghimi S.M., Andersen A.J., Hashemi S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Control. Release 2010, 146:175-181.
2. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
3. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18:567-606.
4. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., Muggia F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14:1430-1437.
5. Szebeni J., Baranyi L., Savay S., Bodo M., Milosevits J., Alving C.R., Bunger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1050-H1058.
6. Szebeni J., Alving C.R., Rosivall L., Bunger R., Baranyi L., Bedocs P., Toth M., Barenholz Y. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 2007, 17:107-117.
7. Moghimi S.M., Hamad I. Liposome-mediated triggering of complement cascade. J. Liposome Res. 2008, 18:195-209.
8. Andersen A.J., Hashemi A.H., Andresen T.L., Hunter A.C., Moghimi S.M. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol. 2009, 5:364-372.
9. Carroll M.V., Sim R.B. Complement in health and disease. Adv. Drug Deliv. Rev. 2011, 63:965-975.
10. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and hemostasis. Nat. Immunol. 2010, 11:785-797.
11. Moghimi S.M., Andersen A.J., Ahmadvand D., Wibroe P.P., Andresen T.L., Hunter A.C. Material properties in complement activation. Adv. Drug Deliv. Rev. 2011, 63:1000-1007.
12. Rybak-Smith M.J., Sim R.B. Complement activation by carbon nanotubes. Adv. Drug Deliv. Rev. 2011, 63:1031-1041.
13. Moghimi S.M., Peer D., Langer R. Reshaping the future of nanopharmaceuticals: ad iudicium. ACS Nano 2011, 5:8454-8458.
14. Moghimi S.M., Hamad I., Andresen T.L., Jørgensen K., Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 2006, 20:2591-2593.
15. Moghimi S.M., Hunter A.C., Dadswell C.M., Savey S., Alving C.R., Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated levels of lipoproteins. Biochim. Biophys. Acta Mol. Basis Dis. 2004, 1689:103-113.
16. Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46:225-232.
17. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
18. Moghimi S.M., Hunter A.C. Complement monitoring of carbon nanotubes. Nat. Nanotechnol. 2010, 5:382-382.
19. Hamad I., Hunter A.C., Rutt K.J., Liu Z., Dai H., Moghimi S.M. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 2008, 45:3797-3803.
20. Arima Y., Toda M., Iwata H. Complement activation on surfaces modifies with ethylene glycol units. Biomaterials 2008, 29:551-560.
21. Moghimi S.M., Szebeni J. Stealth liposomes and nanoparticles: critical issues on protein-binding properties, activation of proteolytic blood cascades and intracellular fate. Prog. Lipid Res. 2003, 42:463-478.
22. Gbadamosi J.K., Hunter A.C., Moghimi S.M. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 2002, 523:338-344.
23. Szebeni J., Alving C.R., Savay S., Barenholz Y., Priev A., Dnino D., Talmon Y. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity. Int. Immunopharmacol. 2001, 1:721-735.
24. Chonn A., Cullis P., Devine D.A. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146:4234-4241.
25. Tedesco F., Fischetti F., Pausa M., Dobrina A., Sim R.B., Daha M.R. Complement-endothelial cell interactions: physiopathological implications. Mol. Immunol. 1999, 36:261-268.
26. Burgi B., Brunner T., Dahinden C.A. The degradation product of the C5a anaphylatoxin C5adesArg retains basophil-activating properties. Eur. J. Immunol. 1994, 24:1583-1589.
27. Mousli M., Hugli T.E., Landry Y., Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol. 1992, 148:2456-2461.
28. Takafuji S., Tadokoro K., Ito K., Dahinden C.A. Degranulation from human eosinophils stimulated with C3a and C5a. Int. Arch. Allergy Immunol. 1994, 104:27-29. [Suppl.].
29. Huber-Lang M.S., Younkin E.M., Sarma J.V., McGuire S.R., Lu K.T., Guo R.F., Padgaonkar V.A., Curnutte J.T., Erickson R., Ward P.A. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 2002, 169:3223-3231.
30. Huber-Lang M., Sarma V.J., Lu K.T., McGuire S.R., Padgaonkar V.A., Guo R.F., Younkin E.M., Kunkel R.G., Ding J., Erickson R., Curnutte J.T., Ward P.A. Role of C5a in multiorgan failure during sepsis. J. Immunol. 2001, 166:1193-1199.
31. Seely A.J., Naud J.F., Campisi G., Giannias B., Liu S., DiCarlo A., Ferri L.E., Pascual J.L., Tchervenkov J., Christou N.V. Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo. Ann. Surg. 2002, 235:550-559.
32. Riedemann N.C., Guo R.F., Bernacki K.D., Ruben J.S., Laudes I.J., Neff T.A., Gao H., Speyer C., Sarma V.J., Zetoune F.S., Ward P.A. Regulation by C5a of neutrophil activation during sepsis. Immunity 2003, 19:193-202.
33. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
34. Moghimi S.M., Hedeman H., Christy N.M., Illum L., Davis S.S. Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J. Leukoc. Biol. 1993, 54:513-517.
35. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Ann. Rev. Pharmacol. Toxicol. 2012, 52:481-503.
36. Moghimi S.M., Murray J.C. Poloxamer-188 revisited: a potentially valuable immune modulator?. J. Natl. Cancer Inst. 1996, 88:766-768.
37. Moghimi S.M., Gray T. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. Clin. Sci. (Lond.) 1997, 93:371-379.
38. Laverman P., Carstens M.G., Storm G., Moghimi S.M. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity: Implications in experimental and clinical oncology. Biochim. Biophys. Acta 2001, 1526:227-229.
39. Pandey S., Agrawal D.A. Immunobiology of Toll-like receptors: emerging trends. Immunol. Cell Biol. 2006, 84:333-341.
40. Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J.D., Wetsel R.A., Miwa T., Song W.-C. regulation of Toll-like receptor-mediated inflammatory responses by complement in vivo. Blood 2007, 110:228-236.
41. Shushakova N., Skokowa J., Schulman J., Baumann U., Zwirner J., Schmidt R.E., Gessner J.E. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcγRs in immune complex-induced lung disease. J. Clin. Invest. 2002, 110:1823-1830.
42. Bharadwaj M., Illing P., Theodossis A., Purcell A.W., Rossjohn J., McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Ann. Rev. Pharmacol. Toxicol. 2012, 52:401-431.
43. Feng J., Sun J., Wang M.Z., Zhang Z., Kim S.-T., Zhu Y., Sun J., Xu J. Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses. Pharmacogenomics 2010, 11:1403-1425.
44. Daly A.K. Using Genome-Wide Association studies to identify genes important in serious adverse drug reactions. Ann. Rev. Pharmacol. Toxicol. 2012, 52:21-35.
45. Immervoll T., Wjst M. Current status of the Asthma and Allergy Database. Nucleic Acid. Res. 1999, 27:213-214.
46. Phimister E.G. Genomic cartography - presenting the HapMap. N. Engl. J. Med. 2005, 353:1766-1768.
47. Thorisson G.A., Smith A.V., Krishnan L., Stein L.D. The International HapMap project Website. Genome Res. 2005, 15:1592-1593.
48. LaFramboise T. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acid. Res. 2009, 37:4181-4193.
49. Kwok P.-Y., Chen X. Detection of single nucleotide polymorphisms. Curr. Issues Mol. Biol. 2003, 5:43-60.
50. Rollins T.E., Siciliano S., Kobayashi S., Cianciarulo D.N., Bonilla-Argudo V., Collier K., Springer M.S. Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:971-975.
51. 2+ influx in neutrophils via a pertusis-toxin-sensitive G protein. Eur. J. Biochem. 1993, 217:289-294.
52. Monk P.N., Scola A.-M., Madala P., Fairlie D.P. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 2007, 152:429-448.
53. Paral D., Sohns B., Crass T., Grove M., Kohl J., Klos A., Bautsch W. Genomic organization of the human C3a receptor. Eur. J. Immunol. 1998, 28:2417-2423.
54. Boulay F., Mery L., Tardif M., Brouchon L., Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 1991, 30:2993-2999.
55. Gerard N.P., Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991, 349:614-617.
56. Surgand J.S., Rodrigo J., Kellenberger E., Rognan D. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins 2006, 62:509-538.
57. Schaefer M., Konrad S., Thalmann J., Rheinheimer C., Johswich K., Sohns B., Klos A. The transcriptional factors AP-1 and Ets are regulators of C3a receptor expression. J. Biol. Chem. 2005, 280:42113-42123.
58. Martin C.B., Ingersoll S.A., Martin B.K. Transcriptional control of C3a receptor gene in glial cells: dependence upon AP-1 but not Ets. Mol. Immunol. 2007, 44:703-712.
59. Hunt J.R., Martin C.B., Martin B.K. Transcriptional regulation of the murine C5a receptor gene: NF-Y is required for basal and LPS induced expression in macrophages and endothelial cells. Mol. Immunol. 2005, 42:1405-1415.
60. Ohno M., Hirata T., Enomoto M., Araki T., Ishimaru H., Takahashi T.A. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immune dendritic cells, but not in mature dendritic cells. Mol. Immunol. 2000, 37:407-412.
61. Lee H., Whitfeld P.L., Mackay C.R. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol. Cell Biol. 2008, 86:153-160.
62. Gerard N.P., Bao L., He X.P., Eddy R.L., Shows T.B., Gerard C. Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene. Biochemistry 1993, 32:1243-1250.
63. Scola A.-M., Higginbottom A., Partridge L.J., Reid C., Woodruff T.M., Taylor S.M., Fairlie D.P., Monk P.N. The role of the N-terminal domain of the complement fragment receptor, C5L2, in ligand binding. J. Biol. Chem. 2007, 282:3664-3671.
64. Gerard N.P., Lu B., Liu P., Craig S., Fujiwara Y., Okinaga S., Gerard C. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 2005, 280:39677-39680.
65. Gao H., Neff T.A., Guo R.F., Speyer C.L., Sarma J.V., Tomlins S., Man Y., Riedemann N.C., Hoesel L.M., Younkin E., Zetoune F.S., Ward P.A. Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 2005, 19:1003-1005.
66. Chen N.J., Mirtsos C., Suh D., Lu Y.C., Lin W.J., McKerlie C., Lee T., Baribault H., Tian H., Yeh W.-C. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007, 446:203-207.
67. Huber-Lang M., Sarma J.V., Rittirsch D., Schreiber H., Weiss M., Flierl M., Younkin E., Schneider M., Suger-Wiedeck H., Gebhard F., McClintock S.D., Neff T., Zetoune F., Bruckner U., Guo R.-F., Monk P.N., Ward P.A. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J. Immunol. 2005, 174:1104-1110.
68. Bachmaier K., Guzman E., Kawamura T., Gao X., Malik A.B. Sphingosine kinase 1 mediation of expression of the anaphylatoxin receptor C5L2 dampens the inflammatory response to endotoxin. PLoS One 2012, 7:e30742.
69. Hawlisch H., Belkaid Y., Baelder R., Hildeman D., Gerard C., Kohl J. C5a negatively regulates Toll-like receptor 4-induced immune responses. Immunity 2005, 22:415-426.
70. Fregonese L., Swan F.J., van Schadewijk A., Dolhnikoff M., Santos M.A., Daha M.R., Stolk J., Tschernig T., Sterk P.J., Hiemstra P.S., Rabe K.F., Mauad T. Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma. J. Allergy Clin. Immunol. 2005, 115:1148-1154.
71. Hasegawa K., Tamari M., Shao C., Shimizu M., Takahashi N., Mao X.-Q., Yamasaki A., Kamada F., Doi S., Fujiwara H., Miyatake A., Fujita K., Tamura G., Matsubara Y., Shirakawa T., Suzuki Y. Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum. Genet. 2004, 115:295-301.
72. Barnes K.C., Caraballo L., Munoz M., Zambelli-Weiner A., Ehrlich E., Burki M., Jimenez S., Mathias R.A., Stockton M.L., Deindl P., Mendoza L., Hershey G.K., Nickel R., Wills-Karp M. A novel promoter polymorphism in the gene encoding complement component 5 receptor 1 on chromosome 19q13.3 is not associated with asthma and atopy in three independent populations. Clin. Exp. Allergy 2004, 34:736-744.
73. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 1993, 20:1-15.
74. Guchelaar H.J., ten Napel C.H., de Vries E.G., Mulder N.H. Clinical, toxicological and pharmaceutical aspects of antineoplastic drug taxol: a review. Clin. Oncol. 1994, 6:40-48.
75. Szebeni J., Muggia F.M., Alving C.R. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 1998, 90:300-306.
76. Karp C.L., Grupe A., Schadt E., Ewart S.L., Keane-Moore M., Cuomo P.J., Kohl J., Wahl L., Kuperman D., Germer S., Aud D., Peltz G., Wills-Karp M. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 2000, 1:221-226.
77. Gavett S.H., O'Hearn D.J., Li X., Huang S.K., Finkelman F.D., Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J. Exp. Med. 1995, 182:1527-1536.
78. Birney E., Andrews D., Caccamo M., Chen Y., Clarke L., Coates G., Cox T., Cunningham F., Curwen V., Cutts T., Down T., Durbin R., Fernandez-Suarez X.M., Flicek P., Gräf S., Hammond M., Herrero J., Howe K., Iyer V., Jekosch K., Kähäri A., Kasprzyk A., Keefe D., Kokocinski F., Kulesha E., London D., Longden I., Melsopp C., Meidl P., Overduin B., Parker A., Proctor G., Prlic A., Rae M., Rios D., Redmond S., Schuster M., Sealy I., Searle S., Severin J., Slater G., Smedley D., Smith J., Stabenau A., Stalker J., Trevanion S., Ureta-Vidal A., Vogel J., White S., Woodwark C., Hubbard T.J.P. Ensembl 2006. Nucleic Acid. Res. 2006, 34:D556-D561.
79. Schuffenecker I., Narod S.A., Ezekowitz R.A., Sobol H., Feunteun J., Lenoir G.M. The gene for mannose-binding protein maps to chromosome 10 and is a marker for multiple endocrine neoplasia type 2. Cytogenet. Cell Genet. 1991, 56:99-102.
80. Vander Crujssen B., Nuytinck L., Boullart L., Elewaut D., Waegeman W., van Thielen M., De Meester E., Lebeer K., Rossau R., De Keyser F. Polymorphisms in ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis. Rheumatology 2007, 46:1792-1795.
81. Litzman J., Freiberger T., Grimbacher B., Gathmann B., Salzer U., Pavlik T., Vlcek J., Postranecka V., Travnickova Z., Thon V. Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency. Clin. Exp. Immunol. 2008, 153:324-330.
82. Chalmers J.D., Kilpatrick D.C., McHugh B.J., Smith M.P., Govan J.R.W., Doherty C., Matsushita M., Hart S.P., Sethi T., Hill A.T. Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis. Thorax 2011, 66:A1-A2. [Suppl.].
83. Ripoche J., Day A., Harris T., Sim R. The complete amino-acid sequence of human-complement factor-H. Biochem. J. 1988, 249:593-602.
84. de Cordoba S., Esparza-Gordillo J., de Jorge E., Lopez-Trascasa M., Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 2004, 41:3553-3567.
85. Reuter M., Caswell C.C., Lukomski S., Zipfel P.F. Binding of the human complement regulators CFHR1 and Factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels. J. Biol. Chem. 2010, 285:38473-38485.
86. Caprioli J., Castelletti F., Bucchioni S., Bettinaglio P., Bresin E., Pianetti G., Gamba S., Brioschi S., Daina E., Remuzzi G., Noris M. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 2003, 12:3385-3395.
87. Sánchez-Corral P., Pérez-Caballero D., Huarte O., Simckes A.M., Goicoechea E., López-Trascasa M., de Córdoba S.R. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2002, 71:1285-1295.
88. Klein R., Zeiss C., Chew E., Tsai J., Sackler R., Haynes C., Henning A., SanGiovanni J., Mane S., Mayne S., Bracken M., Ferris F., Ott J., Barnstable C., Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:3853-3889.
89. Mullins R.F., Aptsiauri N., Hageman G.S. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 2001, 15:3903-3995.
90. Abdelsalam A., Priore L.D., Zarbin M.A. Drusen in Age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv. Ophthalmol. 1999, 44:1-29.
91. Chowers I., Cohen Y., Goldenberg-Cohen N., Vicuna-Kojchen J., Lichtinger A., Weinstein O., Pollack A., Axer-siegel R., Hemo I., Averbukh E., Banin E., Meir T., Lederman M. Association of complement factor H Y402H polymorphism with phenotype of neovscular age related macular degeneration in Israel. Mol. Vis. 2008, 14:1829-1834.
92. Agbeko R.S., Fidler K.J., Allen M.L., Wilson P., Klein N.J., Peters M.J. Genetic variability in complement activation modulates the systemic inflammatory response syndrome in children. Pediatr. Crit. Care Med. 2010, 11:561-567.
93. Volcik K.A., Ballantyne C.M., Braun M.C., Coresh J., Mosley T.H., Boerwinkle E. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: the ARIC study. Am. J. Hypertens. 2008, 21:533-538.
94. Zee R.Y., Diehl K.A., Ridker P.M. Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study. Atherosclerosis 2006, 187:332-335.
95. Lau L.I., Chen S.J., Cheng C.Y., Yen M.Y., Lee F.L., Lin M.W., Hsu W.M., Wei Y.H. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest. Ophthalmol. Vis. Sci. 2006, 47:3242-3246.
96. Kim N.R., Kang J.H., Kwon O.W., Lee S.J., Oh J.H., Chin H.S. Association between complement factor H gene polymorphisms and neovascular age-related macular degeneration in Koreans. Invest. Ophthalmol. Vis. Sci. 2008, 49:2071-2076.
97. Kondo N., Bessho H., Honda S., Negi A. complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2011, 118:339-344.
98. Gotoh N., Yamada R., Hiratani H., Renault V., Kuroiwa S., Monet M., Toyoda S., Chida S., Mandai M., Otani A., Yoshimura N., Matsuda F. No association between factor H gene polymorphism and exudative age-related macular degeneration in Japanese. Hum. Genet. 2006, 120:139-143.
99. Vercellotti G.M., Hammerschmidt D.E., Craddock P.R., Jacob H.S. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood 1982, 59:1299-1304.
100. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007, 28:184-192.
101. Davis A.E., Mejia P., Lu F. Biological activities of C1 inhibitor. Mol. Immunol. 2008, 45:4057-4063.
102. Botto M., Kirschfink M., Macor P., Pickering M.C., Wurzner R., Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol. Immunol. 2009, 46:2774-2783.
103. Cugno M., Zanichelli A., Foieni F., Caccia S., Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol. Med. 2009, 15:69-78.
104. Park K.H., Ryu E., Tosakulwong N., Wu Y., Edwards A.O. Common variation in the SERPING1 gene is not associated with age-related macular degeneration in two independent groups of subjects. Mol. Vis. 2009, 15:200-207.
105. El-Omar E.M., Ng M.T., Hold G.L. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008, 27:244-252.
106. Chen Y.-C., Hsiao C.-C., Chen C.-J., Chin C.-C., Liu S.-F., Wu C.-C., Eng H.-L., Chao T.-Y., Tsen C.-C., Wang Y.-H., Lin M.-C. Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts. BMC Med. Genet. 2010, 11:17.
107. Lorenz E., Mira J.P., Cornish K.L., Arbour N.C., Schwartz D.A. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with Staphylococcal infection. Infect. Immun. 2000, 68:6398-6401.
108. Fageras Bottcher M., Hmani-Aifa M., Lindstrom A., Jenmalm M.C., Mai X.M., Zdolsek H.A., Bjorksten B., Soderkvist P., Vaarala O. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J. Allergy Clin. Immunol. 2004, 114:561-567.
109. Yang I.A., Barton S.J., Rorke S., Cakebread J.A., Keith T.P., Clough J.B., Holgate S.T., Holloway J.W. Toll-like receptor 4 polymorphism and severity of atopy in asthmatics. Genes Immun. 2004, 5:41-45.
110. Takada K., Kaisho T., Akira S. Toll-like receptors. Ann. Rev. Immunol. 2003, 21:335-376.
111. McCurdy J.D., Olynych T.J., Maher L.H., Marshall J.S. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 2003, 170:1625-1629.
112. Varadaradjalou S., Feger S., Thieblemont N., Hamouda N.B., Pleau J.M., Dy M., Arock M. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur. J. Immunol. 2003, 33:899-906.
113. Okumura S., Kashiwakura J., Tomita H., Matsumoto K., Nakajima T., Saito H., Okayama Y. Identification of specific gene expression profiles in human mast cells mediated by Toll-like receptor 4 and FcεRI. Blood 2003, 102:2547-2554.
114. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997, 34:391-399.
115. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3195-3199.
116. Ye R.D. Regulation of nuclear factor κ B activation by G-protein-coupled receptors. J. Leukoc. Biol. 2001, 70:839-848.
117. Hakonarson H., Halapi E., Whelan R., Gulcher J., Stefansson K., Grunstein M.M. Association between IL-1 β/TNF-α-induced glucocorticoid-sensitive changes in multiple gene expression and altered responsiveness in airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 2001, 25:761-771.
118. Silverman E.S., Du J., De Sanctis G.T., Radmark O., Samuelsson B., Drazen J.M., Collins T. Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. Am. J. Respir. Cell Mol. Biol. 1998, 19:316-323.
119. 4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000, 55:S28-S31. [Suppl.].
120. Ingram D.A., Forman M.B., Murray J.J. Activation of complement by Fluosol attributable to the Pluronic detergent micelle structure. J. Cardiovasc. Pharmacol. 1993, 22:456-461.
121. Kent K.M., Cleman M.W., Cowley M.J., Forman M.B., Jaffe C.C., Kaplan M., King S.B., Krucoff M.W., Lasser T., Mcauley B., Smith R., Wisdom C., Wohlgelernter D. Reduction of myocardial ischemia during percutaneous coronary angioplasty with oxygenated Fluosol. Am. J. Cardiol. 1990, 66:279-284.
122. Moghimi S.M., Hamad I., Bunger R., Andresen T.L., Jorgensen K., Hunter A.C., Baranji L., Rosivall L., Szebeni J. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-Modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J. Liposome Res. 2006, 16:167-174.
123. Rangel-Salazar R., Wickstrom-Lindholm M., Aguilar-Salinas C.A., Alvarado-Caudillo Y., Dossing K.B.V., Esteller M., Labourier E., Lund G., Nielsen F.C., Rodriguez-Rios D., Solis-Martinez M.O., Wrobel K., Wrobel K., Zaina S. Human native lipoprotein-induced de novo DNA methylation is associated with repression of inflammatory genes in THP-1 macrophages. BMC Genomics 2011, 12:582.
124. Stenvinkel P., Karimi M., Johansson S., Axelsson J., Suliman M., Lindholm B., Heimburger O., Barany P., Alvestrand A., Nordfors L., Qureshi A.R., Ekstrom T.J., Schalling M. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. J. Intern. Med. 2007, 261:488-499.
125. Isaacson W. Steve Jobs 2011, Simon & Schuster, New York.